ConductScience.org, home

Paper39199348

Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.

Gu Y and 6 others. Biomolecules, 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment. Papers, record 39199348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199348

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.
PubMed
Journal
Biomolecules
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
2.04, provisional
iCite
Revised in PubMed
2026-04-09
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gu YYunan
2Du LLixin
3Wu YYuxin
4Qin JJuan
5Gu XXiang
6Guo ZZhihua
7Li YYahttps://orcid.org/0009-0005-8684-9308

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Drug Delivery SystemsMajor topic
Humans
Biomimetic Materials
Biomimetics
Animals
Nanomedicine
Nanoparticles
Nanoparticle Drug Delivery System

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82174343National Natural Science Foundation of ChinaPubMed
202302Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese MedicinePubMed
CX20230830Postgraduate Scientific Research Innovation Project of Hunan ProvincePubMed
S202310541090Hunan University students innovation and entrepreneurship training programPubMed
D202303017861Scientific Research Topics of Hunan Provincial Health and Wellness CommissionPubMed

Source PubMed

Download CSV of grants

References144

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129408473Curcumin marinosomes as promising nano-drug delivery system for lung cancer.Int J Pharm2018https://conductscience.org/library/papers/29408473PubMed
228860319Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease.Circ Res2017https://conductscience.org/library/papers/28860319PubMed
337515961A erythrocyte-platelet hybrid membrane coated biomimetic nanosystem based on ginsenosides and PFH combined with ultrasound for targeted delivery in thrombus therapy.Colloids Surf B Biointerfaces2023https://conductscience.org/library/papers/37515961PubMed
435354074Neighborhood-level Social Vulnerability and Prevalence of Cardiovascular Risk Factors and Coronary Heart Disease.Curr Probl Cardiol2023https://conductscience.org/library/papers/35354074PubMed
528382729Gold nanoparticles in cardiovascular imaging.Wiley Interdiscip Rev Nanomed Nanobiotechnol2018https://conductscience.org/library/papers/28382729PubMed
634236248Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment.Drug Deliv2021https://conductscience.org/library/papers/34236248PubMed
727544847(-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice.Int J Pharm2016https://conductscience.org/library/papers/27544847PubMed
836898531Anti-CXCR2 antibody-coated nanoparticles with an erythrocyte-platelet hybrid membrane layer for atherosclerosis therapy.J Control Release2023https://conductscience.org/library/papers/36898531PubMed
936103910Stem cell membrane-coated abiotic nanomaterials for biomedical applications.J Control Release2022https://conductscience.org/library/papers/36103910PubMed
1037527612
Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials.
Atherosclerosis2023https://conductscience.org/library/papers/37527612PubMed
1132730849Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting.Adv Drug Deliv Rev2020https://conductscience.org/library/papers/32730849PubMed
1229700074Emerging Role of Precision Medicine in Cardiovascular Disease.Circ Res2018https://conductscience.org/library/papers/29700074PubMed
1338223291Precision cardiac targeting: empowering curcumin therapy through smart exosome-mediated drug delivery in myocardial infarction.Regen Biomater2024https://conductscience.org/library/papers/38223291PubMed
1431427727Counter-regulatory renin-angiotensin system in cardiovascular disease.Nat Rev Cardiol2020https://conductscience.org/library/papers/31427727PubMed
1535511857Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.Eur Heart J2022https://conductscience.org/library/papers/35511857PubMed
1636924328Drug loaded implantable devices to treat cardiovascular disease.Expert Opin Drug Deliv2023https://conductscience.org/library/papers/36924328PubMed
1738614985Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE-/- Mice.J Nanobiotechnology2024https://conductscience.org/library/papers/38614985PubMed
1836575429Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment.J Nanobiotechnology2022https://conductscience.org/library/papers/36575429PubMed
1934286950Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics.ACS Appl Mater Interfaces2021https://conductscience.org/library/papers/34286950PubMed
2032263201A novel multifunctional biomimetic Au@BSA nanocarrier as a potential siRNA theranostic nanoplatform.J Mater Chem B2016https://conductscience.org/library/papers/32263201PubMed

See all 144 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42909371Cell-derived biomimetic nanomedicines: Emerging theranostic platforms for precision management of atherosclerosis.Theranostics2026https://conductscience.org/library/papers/42909371PubMed
42579251Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.Discov Nano2026https://conductscience.org/library/papers/42579251PubMed
42333862Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine.J Appl Biomed2026https://conductscience.org/library/papers/42333862PubMed
42016346Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.Int J Nanomedicine2026https://conductscience.org/library/papers/42016346PubMed
41906208Biomimetic materials for medical applications.Chin Med J (Engl)2026https://conductscience.org/library/papers/41906208PubMed
41340638Harnessing nature's blueprint: Unlocking the potential of subcellular structure membrane-coated nanosystems for precision medicine.Bioact Mater2026https://conductscience.org/library/papers/41340638PubMed
41229674Macrophage Membrane-Coated Nanocarriers in Myocardial Infarction: A Paradigm Shift in Targeted Cardiac Therapy.Int J Nanomedicine2025https://conductscience.org/library/papers/41229674PubMed
40909219Biomimetic membrane nanotechnology in cerebral ischemic stroke:a promising technology for therapeutic treatment and diagnosis.Front Bioeng Biotechnol2025https://conductscience.org/library/papers/40909219PubMed
40137371Fabrication and Characterization of Immature Porcine Cartilage-Derived Cell Biomembranes.J Funct Biomater2025https://conductscience.org/library/papers/40137371PubMed
40125442How Advanced Is Nanomedicine for Atherosclerosis?Int J Nanomedicine2025https://conductscience.org/library/papers/40125442PubMed
40050980SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.J Nanobiotechnology2025https://conductscience.org/library/papers/40050980PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39199348

GET https://conductscience.org/api/papers/v1/39199348/references?page=2